NewKerala.com

Key Points

Zydus Lifesciences has reported its Q4 financial performance with mixed results. The company saw an 18% revenue increase despite a marginal net profit decline. Managing Director Dr. Sharvil Patel highlighted the company's strong operational performance and growth across business segments. The firm also recommended a final dividend of Rs 11 per share, demonstrating confidence in its financial health.

Key Points: Zydus Lifesciences Q4 Revenue Rises 18% Despite Profit Dip

  • Revenue jumps 18% to Rs 6,527.9 crore in Q4
  • Net profit slightly declines to Rs 1,170.9 crore
  • R&D investments reach Rs 1,855.5 crore
  • Final dividend of Rs 11 per share recommended
2 min read

Zydus Lifesciences Q4 net profit drops to Rs 1,170.9 crore, expenses up

Zydus Lifesciences reports Q4 financial results with revenue growth, final dividend recommendation, and strong R&D investments

"We ended FY25 on a strong note with all business segments exceeding growth expectations - Dr. Sharvil Patel, Managing Director"

Mumbai, May 20

Multinational pharmaceutical company Zydus Lifesciences Limited on Tuesday reported a 0.96 per cent decline in net profit to Rs 1,170.9 crore for the fourth quarter (Q4) of FY25, from Rs 1,182.3 crore in the same quarter last fiscal (Q4 FY25).

The company's total expenses in Q4 rose by approximately 13.86 per cent to Rs 4,716.9 crore from Rs 4,143.2 crore in the same quarter last fiscal, according to its stock exchange filing.

For the full financial year, total expenses increased to Rs 17,264.7 crore in FY25 from Rs 15,008.4 crore in FY24 -- a rise of about 15.04 per cent.

However, revenue from operations rose nearly 18 per cent to Rs 6,527.9 crore in Q4, compared to Rs 5,533.8 crore in Q4FY24.

The board of Zydus has recommended a final dividend of Rs 11 per equity share for FY25.

"The dividend is subject to shareholder approval at the upcoming Annual General Meeting (AGM) scheduled for August 12. The record date for the dividend is July 25, and payment is expected on or around August 14," the company said in its regulatory filing.

Zydus posted earnings before interest, taxes, depreciation, and amortisation (EBITDA) of Rs 2,126 crore for the same quarter.

For the full financial year, the Ahmedabad-headquartered firm recorded a 19 per cent rise in revenue from operations to Rs 23,241.5 crore.

Its adjusted net profit rose 23 per cent year-on-year (YoY) to Rs 4,745.1 crore. The company's investments in research and development stood at Rs 1,855.5 crore, accounting for 8 per cent of its revenues, while its organic capital expenditure reached Rs 1,214 crore.

Zydus Managing Director Dr. Sharvil Patel said the company ended FY25 on a strong note, with all business segments exceeding growth expectations.

He added that the success of their product portfolio and operational efficiency boosted profitability.

He also noted progress in their differentiated product pipeline and long-term capabilities.

- IANS

Share this article:

Reader Comments

R
Rahul K.
Not worried about the slight profit dip when revenue grew 18%! Shows Zydus is investing in future growth. Their R&D spending at 8% of revenue is impressive for an Indian pharma company. More power to Make in India medicines! 🇮🇳
P
Priya M.
Expenses up 15% while profit only down 1%? Actually shows good cost management. The dividend of ₹11/share is decent too. Holding my Zydus stocks for long term - their US generic pipeline looks strong.
S
Sanjay T.
As someone from Ahmedabad, proud to see our homegrown pharma giant doing well globally! But management should explain the expense jump - is it raw material costs or expansion related? Transparency matters for retail investors like us.
A
Ananya R.
Their COVID vaccine was a lifesaver for my elderly parents. Hope they continue focusing on affordable medicines for India while expanding globally. Profit margins can wait, public health comes first! 🙏
V
Vikram J.
₹1,855 crore in R&D is good but how much goes to cancer/diabetes drugs vs just copying Western patents? Indian companies should lead in innovation, not just generics. Still, better numbers than I expected!
N
Neha P.
The real story is the 23% adjusted net profit growth for full year! Quarterly numbers can fluctuate. As a medical rep, I've seen Zydus products gaining trust in tier 2/3 cities. Rural penetration strategy is working well 💊

We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.

Leave a Comment

Minimum 50 characters 0/50